These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

675 related items for PubMed ID: 20406835

  • 1. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J.
    Clin Cancer Res; 2010 May 01; 16(9):2646-55. PubMed ID: 20406835
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy.
    Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, Hershkovitz L, Treves AJ, Shalmon B, Zippel D, Markel G, Shapira-Frommer R, Schachter J, Besser MJ.
    J Immunother; 2011 Mar 01; 34(2):212-20. PubMed ID: 21304398
    [Abstract] [Full Text] [Related]

  • 4. Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center.
    Besser MJ, Treves AJ, Itzhaki O, Hardan I, Nagler A, Papa MZ, Catane R, Winkler E, Shalmon-Zifroni B, Schachter J.
    Isr Med Assoc J; 2006 Mar 01; 8(3):164-8. PubMed ID: 16599050
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tumor tissue recycling--a new combination treatment for solid tumors: experimental and preliminary clinical research.
    Li B, Ding J, Larson A, Song S.
    In Vivo; 1999 Mar 01; 13(5):433-8. PubMed ID: 10654199
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Flow cytometry assessment of residual melanoma cells in tumor-infiltrating lymphocyte cultures.
    Richards JO, Treisman J, Garlie N, Hanson JP, Oaks MK.
    Cytometry A; 2012 May 01; 81(5):374-81. PubMed ID: 22467596
    [Abstract] [Full Text] [Related]

  • 14. [Application of gene therapy in tumor adoptive immunotherapy].
    Wang C, Zhao Y.
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr 01; 25(2):482-6. PubMed ID: 18610648
    [Abstract] [Full Text] [Related]

  • 15. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
    Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA.
    Clin Cancer Res; 2010 Dec 15; 16(24):6122-31. PubMed ID: 20668005
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
    Nguyen LT, Saibil SD, Sotov V, Le MX, Khoja L, Ghazarian D, Bonilla L, Majeed H, Hogg D, Joshua AM, Crump M, Franke N, Spreafico A, Hansen A, Al-Habeeb A, Leong W, Easson A, Reedijk M, Goldstein DP, McCready D, Yasufuku K, Waddell T, Cypel M, Pierre A, Zhang B, Boross-Harmer S, Cipollone J, Nelles M, Scheid E, Fyrsta M, Lo CS, Nie J, Yam JY, Yen PH, Gray D, Motta V, Elford AR, DeLuca S, Wang L, Effendi S, Ellenchery R, Hirano N, Ohashi PS, Butler MO.
    Cancer Immunol Immunother; 2019 May 15; 68(5):773-785. PubMed ID: 30747243
    [Abstract] [Full Text] [Related]

  • 18. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS, White DE, Hurst R, Rosenberg SA, Yang JC.
    Cancer J Sci Am; 1998 May 15; 4(2):86-93. PubMed ID: 9532410
    [Abstract] [Full Text] [Related]

  • 19. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.
    J Immunother; 2006 May 15; 29(5):545-57. PubMed ID: 16971810
    [Abstract] [Full Text] [Related]

  • 20. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.
    Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL.
    N Engl J Med; 1990 Aug 30; 323(9):570-8. PubMed ID: 2381442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.